Inflammatory Bowel Diseases (IBD) and the Microbiome-Searching the Crime Scene for Clues.

Inflammatory bowel diseases (IBD) develop via convergence of environmental, microbial, immunological, and genetic factors. Alterations in the gut microbiota have been associated with development and progression of IBD, but it is not clear which populations of microbes are involved or how they might contribute to IBD. We review the genetic and environmental factors affecting the gut microbiota, the roles of gut microbes and their bioproducts in the development and clinical course of IBD, and strategies by which microbiome-based therapies can be used to prevent, manage, and eventually cure IBD. We discuss research findings that help bridge the gap between the basic sciences and clinical application.

Lee M ，Chang EB 《-》

Gut microbiota and inflammatory bowel disease: so far so gut!

Holleran G ，Lopetuso LR ，Ianiro G ，Pecere S ，Pizzoferrato M ，Petito V ，Graziani C ，McNAMARA D ，Gasbarrini A ，Scaldaferri F ... -  《-》

Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases.

Mishima Y ，Sartor RB 《-》

Links Between Inflammatory Bowel Disease and Chronic Obstructive Pulmonary Disease.

Inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD) are chronic inflammatory diseases of the gastrointestinal and respiratory tracts, respectively. These mucosal tissues bear commonalities in embryology, structure and physiology. Inherent similarities in immune responses at the two sites, as well as overlapping environmental risk factors, help to explain the increase in prevalence of IBD amongst COPD patients. Over the past decade, a tremendous amount of research has been conducted to define the microbiological makeup of the intestine, known as the intestinal microbiota, and determine its contribution to health and disease. Intestinal microbial dysbiosis is now known to be associated with IBD where it impacts upon intestinal epithelial barrier integrity and leads to augmented immune responses and the perpetuation of chronic inflammation. While much less is known about the lung microbiota, like the intestine, it has its own distinct, diverse microflora, with dysbiosis being reported in respiratory disease settings such as COPD. Recent research has begun to delineate the interaction or crosstalk between the lung and the intestine and how this may influence, or be influenced by, the microbiota. It is now known that microbial products and metabolites can be transferred from the intestine to the lung via the bloodstream, providing a mechanism for communication. While recent studies indicate that intestinal microbiota can influence respiratory health, intestinal dysbiosis in COPD has not yet been described although it is anticipated since factors that lead to dysbiosis are similarly associated with COPD. This review will focus on the gut-lung axis in the context of IBD and COPD, highlighting the role of environmental and genetic factors and the impact of microbial dysbiosis on chronic inflammation in the intestinal tract and lung.

Raftery AL ，Tsantikos E ，Harris NL ，Hibbs ML ... -  《Frontiers in Immunology》

Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.

Eom T ，Kim YS ，Choi CH ，Sadowsky MJ ，Unno T ... -  《-》